AZD3759 + AZD9291
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Conditions
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Trial Timeline
Nov 5, 2014 → Oct 28, 2020
NCT ID
NCT02228369About AZD3759 + AZD9291
AZD3759 + AZD9291 is a phase 1 stage product being developed by AstraZeneca for EGFR Mutation Positive Advanced Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02228369. Target conditions include EGFR Mutation Positive Advanced Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02228369 | Phase 1 | Completed |
Competing Products
20 competing products in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH25448 | Yuhan | Phase 1/2 | 41 |
| YH32364 | Yuhan | Phase 1/2 | 41 |
| Datopotamab deruxtecan | Daiichi Sankyo | Pre-clinical | 23 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8273 | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| ASP8273 Capsules + ASP8273 Capsules A | Astellas Pharma | Phase 2 | 52 |
| famitinib po + HS-10296 po | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| AZD9291 40 mg + AZD9291 80 mg | AstraZeneca | Phase 1 | 33 |
| Osimertinib-based adaptive treatment + Osimertinib 80 MG | AstraZeneca | Phase 2 | 52 |
| AZD9291 + MEDI4736 | AstraZeneca | Phase 3 | 77 |
| EGFR TKIs (gefitinib, erlotinib, afatinib, et al) | AstraZeneca | Pre-clinical | 23 |
| AZD9291 | AstraZeneca | Pre-clinical | 23 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| Dasatinib + Osimertinib | AstraZeneca | Phase 1/2 | 41 |
| AZD9291 80mg oral each day | AstraZeneca | Phase 3 | 77 |
| Tremelimumab + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |